Cyxone AB (Sweden) Insiders
| CYXO Stock | SEK 0.03 0 5.08% |
Cyxone AB employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 36 years, averaging almost 4.0 years of service per executive, having 1.0 employees per reported executive. Breaking down Cyxone AB's management performance can provide insight into the firm performance.
| Ola Skanung CEO Interim Chief Executive Officer, Chief Financial Officer |
| Bert Junno Chairman Chairman of the Board |
Cyxone |
Cyxone AB Management Team Effectiveness
The company has return on total asset (ROA) of (0.5861) % which means that it has lost $0.5861 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.0658) %, meaning that it generated substantial loss on money invested by shareholders. Cyxone AB's management efficiency ratios could be used to measure how well Cyxone AB manages its routine affairs as well as how well it operates its assets and liabilities.Cyxone AB Workforce Comparison
Cyxone AB is number one stock in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 1,236. Cyxone AB maintains roughly 8.0 in number of employees contributing less than 1% to stocks in Biotechnology industry.
Cyxone AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Cyxone AB Price Series Summation is a cross summation of Cyxone AB price series and its benchmark/peer.
Cyxone AB Notable Stakeholders
A Cyxone AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Cyxone AB often face trade-offs trying to please all of them. Cyxone AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Cyxone AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Ola Skanung | Interim Chief Executive Officer, Chief Financial Officer | Profile | |
| Bert Junno | Chairman of the Board | Profile | |
| Theresa Olsen | Director | Profile | |
| Mikael Lindstam | Chief Operating Officer, Director | Profile | |
| Saad Gilani | Director | Profile | |
| Malin Berthold | Project Manager | Profile | |
| Erika Samuelsson | Chief Officer | Profile | |
| CarlMagnus Hogerkorp | COO CEO | Profile |
About Cyxone AB Management Performance
The success or failure of an entity such as Cyxone AB often depends on how effective the management is. Cyxone AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Cyxone management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Cyxone management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Cyxone AB , a clinical biotech company, develops disease modifying therapies for rheumatoid arthritis and multiple sclerosis and treatments for virally induced acute respiratory disorders. The company was founded in 2015 and is headquartered in Malm, Sweden. Cyxone AB is traded on Stockholm Stock Exchange in Sweden.
Please note, the imprecision that can be found in Cyxone AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cyxone AB. Check Cyxone AB's Beneish M Score to see the likelihood of Cyxone AB's management manipulating its earnings.
Cyxone AB Workforce Analysis
Traditionally, organizations such as Cyxone AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Cyxone AB within its industry.Cyxone AB Manpower Efficiency
Return on Cyxone AB Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 5.6M | |
| Net Loss Per Executive | 5.6M |
Additional Tools for Cyxone Stock Analysis
When running Cyxone AB's price analysis, check to measure Cyxone AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyxone AB is operating at the current time. Most of Cyxone AB's value examination focuses on studying past and present price action to predict the probability of Cyxone AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyxone AB's price. Additionally, you may evaluate how the addition of Cyxone AB to your portfolios can decrease your overall portfolio volatility.